Lack of Binding of Methapyrilene and Similar Antihistamines to Rat Liver DNA Examined by 32Ppostlabeling1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Diphenhydramine Hydrochloride (CASRN 147-24-0) in F344/N Rats
NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 355 TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) LJ.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP ‘TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) R. Melnick, Ph.D., Study Scientist NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 September 1989 NTP TR 355 NIH Publication No. 89-2810 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .................. 6 CONTRIBUTORS ............................................................ 7 PEERREVIEWPANEL ........................................................ 8 SUMMARY OF PEER REVIEW COMMENTS ......................................... 9 I. INTRODUCTION ........................................................ 11 I1. MATERIALS AND METHODS .............................................. 21 III. RESULTS ............................................................. 35 RATS ............................................................. 36 MICE ............................................................. 45 GENETIC TOXICOLOGY ............................................... 53 IV. -
(12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S. -
Food and Drug Administration, HHS § 310.201
Food and Drug Administration, HHS § 310.201 (d) Prescription legend not allowed on (v) The preparation is labeled with exempted drugs. The use of the prescrip- adequate directions for use in minor tion caution statement quoted in sec- conditions as a simple analgesic. tion 503(b) (4) of the act, in the labeling (vi) The dosages of N-acetyl-p-amino- of a drug exempted under the provi- phenol recommended or suggested in sions of this section, constitutes mis- the labeling do not exceed: For adults, branding. Any other statement or sug- 0.65 gram (10 grains) per dose or 2.6 gestion in the labeling of a drug ex- grams (40 grains) per 24-hour period: for empted under this section, that such children 6 to 12 years of age, one-half of drug is limited to prescription use, the maximum adult dose or dosage; for may constitute misbranding. children 3 to 6 years of age, one-fifth of (e) Prescription-exemption procedure of the maximum adult dose or dosage. OTC drug review. A drug limited to pre- (vii) The labeling bears, in juxtaposi- scription use under section 503(b)(1)(B) tion with the dosage recommendations, of the act may also be exempted from a clear warning statement against ad- prescription-dispensing requirements ministration of the drug to children by the procedure set forth in § 330.13 of under 3 years of age and against use of this chapter. the drug for more than 10 days, unless such uses are directed by a physician. [39 FR 11680, Mar. -
Meeting Materials)
California State Board of Pharmacy BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY 1625 N. Market Blvd, N219, Sacramento, CA 95834 DEPARTMENT OF CONSUMER AFFAIRS Phone: (916) 574-7900 GOVERNOR EDMUND G. BROWN JR. Fax: (916) 574-8618 www.pharmacy.ca.gov ENFORCEMENT AND COMPOUNDING COMMITTEE REPORT April 18, 2017 Amy Gutierrez, PharmD, Licensee Member, Chair Allen Schaad, Licensee Member, Vice Chair Greg Lippe, Public Member Stan Weisser, Licensee Member Valerie Muñoz, Public Member Ricardo Sanchez, Public Member I. Call to Order, Establishment of Quorum, and General Announcements II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)] III. Enforcement Matters a. University of California, San Diego’s Pilot Program to Permit Patients to Access Medications from an Automated Drug Delivery System Not Immediately Adjacent to the Pharmacy Background At the April 2015 Board Meeting, the board approved an 18-month pilot study under the auspices of the University of California, San Diego (UCSD) School of Pharmacy involving use of an automated drug delivery system (ADDS) for prescription medication from which staff of Sharp Hospital in San Diego and their families, who opted in, could pick up their outpatient medications. Consultation would be provided via telephone before medication could be dispensed to a patient for first time fills. Since that time the committee has received quarterly updates on the study, including usage of the system. -
Author Index Page Numbers in Italics Refer to Bibliography
Author Index Page Numbers in italics refer to bibliography Aaron,T.H., Criep,L.H. 180. Adams,M.R., see Litchfield,J. Albert,A., Serjeant,E.P. 176, 207 T., Jr. 386, 409, 432, 441, 207 Aaron, T. H., see Criep, L. H. 465,496 Albert,J.R., see Lish,P.M. 398,427 Adamson,D.W., Barrett,P.A., 449, 465, 466, 495 Aarsen,P.N., Zeegers,A. 15, Billinghurst, J. W., Green, A. Albert, U., see Giertz, H. 444, 30 F .. Jones,T.S.G. 190,192, 489 Abbozzo, G., Genazzani, E., 207 Alberty,J. 387,425, 442, Donatelli, L. 562,570 Adamson, D. W., Barrett, P. A., 452--455,480 Abdel-Galil, A. A. M., Marshall, Billinghurst,J. W., Jones, T. Alberty, J., Huurrekorpi, L. P. B. 114, 122 S.G. 190,207 399, 425, 455, 480 Aborg, e.-H .. Novotny,J., Adamson, D. W., Billinghurst, Alberty,J., Schiede,M. 399, Uvniis,B. 86.90 J.W. 189,194,207 425,455,480 Aborg,e. H., Uvniis,B. 87, 90 Adashek, D., Grossman, M. I. Alberty, J., Takkunen, R. 467, Aborg, C.-H., see Uvniis,B. 58. 46,47,55 480 74. 75, 82, 84-87. 92 Adlerova, E., see Protiva, M. Albinus,M., Sewing.K.F. 2, Abram, L. E., see Cohen, M. B. 201, 212 3, 6, 8, 11, 21, 30, 264, 287, 421,427 Ado,A.D., Abrossimow,W.N. 463,480 Abrams,G., see Lear,E. 566, 453.480 Albrecht, I., see Cort, J. H. 579, 571 Ado, A. D., Ishimova, L. M., 597 Abramson, D. -
Methapyrilene Hydrochloride (CAS No
National Toxicology Program Toxicity Report Series Number 46 NTP Technical Report on the Hepatotoxicity Studies of the Liver Carcinogen Methapyrilene Hydrochloride (CAS No. 135-23-9) Administered in Feed to Male F344/N Rats July 2000 U.S. Department of Health and Human Services Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Toxicity Study Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. -
The Organic Chemistry of Drug Synthesis
The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date. -
A Comparison of Drug Use in Driver Fatalities and Similarly Exposed Drivers
DOT HS-802 488 A COMPARISON OF DRUG USE IN DRIVER FATALITIES AND SIMILARLY EXPOSED DRIVERS Contract No. DOT-HS-4-00941 July 1977 Final Report PREPARED FOR: U.S. DEPARTMENT OF TRANSPORTATION NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION WASHINGTON, D.C. 20590 Document is available to the public through the National Technical Information Service, Springfield, Virginia 22161 This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange. The United States Govern ment assumes no liability for its contents or use thereof. Technical Report Documentation Page 1. Report No. 2. Goeemm.nt Accession No. 3. Recipient's Catalog No. DOT HS-802 488 -^. 1. Title and Subtitle 5. Report Date July 1977 A COMPARISON OF DRU^ USE IN DRIVER FATALITIES 6. Performing Organization Code AND SIMILARLY EXPOSED DRIVERS . B. Performing Organization Report No. 7. Authorrs) Robert R. Blackburn, Edward J. Woodhouse 3963-D 9. Performing Organization Name and Address 10. Worb Unit No. (TRAIS) Midwest Research Institute I). Contract at Grant No. 425 Volker Boulevard DOT-HS-4-00941 Kansas City, Missouri 64110 13. Type of Report and Period Covered 12. Sponsoring Agency Name and Address 28 June 1974-25 March 1977 i U.S. Department of Transportation National Highway Traffic Safety Administration Final Report Washington, D.C. 20590 14. Sponsoring Agency Code 15. supplementary Notes 16. Abstract Crash information, urine, blood and bile samples from 900 fatally injured drivers were collected by medical examiners in 22 areas of the country. Ran domly selected living drivers were interviewed at times and places of recent fatal crashes in Dallas, Texas, and Memphis, Tennessee and breath, urine, and blood samples were obtained. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr. -
| Hao Ha Ta Maria Tai Mai Multe Detalian Mature
|HAO HA TA MARIAUS009730892B2 TAI MAI MULTE DETALIAN MATURE (12 ) United States Patent ( 10 ) Patent No. : US 9 , 730 ,892 B2 Schutt et al. ( 45 ) Date of Patent : Aug . 15 , 2017 (54 ) METHOD FOR FORMULATING LARGE ( 56 ) References Cited DIAMETER SYNTHETIC MEMBRANE VESICLES U . S . PATENT DOCUMENTS 2 ,044 , 296 A 6 /1936 Hardgrove ( 71 ) Applicant : Pacira Pharmaceuticals , Inc ., San 2 ,824 ,807 A 2 / 1958 Laster et al . Diego , CA (US ) ( Continued ) (72 ) Inventors : Ernest George Schutt , San Diego , CA (US ) ; Ronald Warren McGuire , FOREIGN PATENT DOCUMENTS Murrieta , CA (US ) ; Peter Andrew AU 2002301268 B2 2 /2003 Walters, San Diego , CA (US ) ; AU 2006200044 Al 2 / 2006 Kathleen D . A . Los, San Diego , CA CA 933796 9 / 1973 ?? 960811 1 / 1975 (US ) CA 2 564 120 A1 8 / 1998 CA 2464668 5 / 2003 (73 ) Assignee : Pacira Pharmaceuticals , Inc ., San CH 519936 7 / 1971 Diego , CA (US ) CH 587023 7 / 1974 CN 101396345 5 / 2009 DE 1199191 8 / 1965 ( * ) Notice : Subject to any disclaimer, the term of this DE 51254 10 / 1966 patent is extended or adjusted under 35 DE 56223 5 / 1967 U . S . C . 154 ( b ) by 0 days . ( Continued ) ( 21 ) Appl . No . : 15 / 249 , 195 OTHER PUBLICATIONS Aug . 26 , 2016 (22 ) Filed : Atiemo -Obeng et al. “ Rotor - Stator Mixing Devices ” , Handbook of (65 ) Prior Publication Data Industrial Mixing Science and Practice , 2004 , 479 - 505 , Eds. Paul , US 2016 /0361260 A1 Dec . 15 , 2016 et al. , Hoboken , NJ: John Wiley and Sons , Inc. Related U . S . Application Data (Continued ) (63 ) Continuation of application No. 13 / 786 ,378 , filed on Primary Examiner — Monzer R Chorbaji Mar . -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.